Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Shapiro

Showing results (11-20 of 160) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspectiveCharles L Shapiro
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Is pamidronate effective in preventing chemotherapy-induced bone loss?Charles L Shapiro
Seminars in Oncology|December 10, 2003
Osteopenia and osteoporosis in women with breast cancerBhuvaneswari Ramaswamy, Charles L Shapiro
Gland Surgery|September 4, 2018
Osteoporosis and musculoskeletal complications related to therapy of breast cancerJohanna Suskin, Charles L Shapiro
Drugs|December 20, 2008
Aromatase inhibitor-associated bone loss: clinical considerationsShubham Pant, Charles L Shapiro
Oncology (Williston Park, N.Y.)|October 23, 2003
Bisphosphonates in the prevention and treatment of bone metastasesBhuvaneswari Ramaswamy, Charles L Shapiro
Clinical Breast Cancer|December 4, 2003
Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancerBhuvaneswari Ramaswamy, Charles L Shapiro
Current Osteoporosis Reports|October 16, 2013
Skeletal manifestations of treatment of breast cancer on premenopausal womenLoomee Doo, Charles L Shapiro
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Survivorship and complications of treatment in breast cancerEwa Mrozek, Charles L Shapiro
Oncology (Williston Park, N.Y.)|June 13, 2003
Rationale for mitomycin and irinotecan use in advanced breast cancerYiqing Xu, Charles L Shapiro
Pageof 16

Showing results (11-20 of 160) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspectiveCharles L Shapiro
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Is pamidronate effective in preventing chemotherapy-induced bone loss?Charles L Shapiro
Seminars in Oncology|December 10, 2003
Osteopenia and osteoporosis in women with breast cancerBhuvaneswari Ramaswamy, Charles L Shapiro
Gland Surgery|September 4, 2018
Osteoporosis and musculoskeletal complications related to therapy of breast cancerJohanna Suskin, Charles L Shapiro
Drugs|December 20, 2008
Aromatase inhibitor-associated bone loss: clinical considerationsShubham Pant, Charles L Shapiro
Oncology (Williston Park, N.Y.)|October 23, 2003
Bisphosphonates in the prevention and treatment of bone metastasesBhuvaneswari Ramaswamy, Charles L Shapiro
Clinical Breast Cancer|December 4, 2003
Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancerBhuvaneswari Ramaswamy, Charles L Shapiro
Current Osteoporosis Reports|October 16, 2013
Skeletal manifestations of treatment of breast cancer on premenopausal womenLoomee Doo, Charles L Shapiro
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Survivorship and complications of treatment in breast cancerEwa Mrozek, Charles L Shapiro
Oncology (Williston Park, N.Y.)|June 13, 2003
Rationale for mitomycin and irinotecan use in advanced breast cancerYiqing Xu, Charles L Shapiro
Pageof 16